Literature DB >> 25623214

Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.

Marco Dal Molin1, Ming Zhang2, Roeland F de Wilde1, Niki A Ottenhof1, Neda Rezaee3, Christopher L Wolfgang3, Amanda Blackford2, Bert Vogelstein2, Kenneth W Kinzler2, Nickolas Papadopoulos2, Ralph H Hruban1, Anirban Maitra4, Laura D Wood5.   

Abstract

PURPOSE: The median survival following surgical resection of pancreatic ductal adenocarcinoma (PDAC) is currently <20 months. However, survival ≥10 years is achieved by a small subset of patients who are defined as very long-term survivors (VLTS). The goal of this study was to determine whether specific genetic alterations in resected PDACs determined very long-term survival. EXPERIMENTAL
DESIGN: We sequenced the exomes of eight PDACs from patients who survived ≥10 years. On the basis of the results of the exomic analysis, targeted sequencing of selected genes was performed in a series of 27 additional PDACs from VLTSs.
RESULTS: KRAS mutations were identified in 33 of 35 cancers (94%) from VLTSs and represented the most prevalent alteration in our cohort. TP53, SMAD4, and CDKN2A mutations occurred in 69%, 26%, and 17%, respectively. Mutations in RNF43, which have been previously associated with intraductal papillary mucinous neoplasms, were identified in four of the 35 cancers (11%). Taken together, our data show no difference in somatic mutations in carcinomas from VLTSs compared with available data from PDACs unselected for survival. Comparison of clinicopathologic features between VLTSs and a matching control group demonstrated that younger age, earlier stage, well/moderate grade of differentiation, and negative resection margins were associated with VLTS. However, more advanced stage, poor grade, or nodal disease did not preclude long-term survival.
CONCLUSIONS: Our results suggest that in most patients, somatic mutations in commonly mutated genes are unlikely to be the primary determinant of very long-term survival following surgical resection of PDAC. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25623214      PMCID: PMC4401626          DOI: 10.1158/1078-0432.CCR-14-2600

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Fanconi anemia gene mutations in young-onset pancreatic cancer.

Authors:  Michiel S van der Heijden; Charles J Yeo; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

2.  Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Authors:  Shinichi Yachida; Catherine M White; Yoshiki Naito; Yi Zhong; Jacqueline A Brosnan; Anne M Macgregor-Das; Richard A Morgan; Tyler Saunders; Daniel A Laheru; Joseph M Herman; Ralph H Hruban; Alison P Klein; Siân Jones; Victor Velculescu; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2012-09-18       Impact factor: 12.531

3.  Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future.

Authors:  Shayna L Showalter; Sarah Charles; Justin Belin; Joseph Cozzitorto; Peter Einstein; Nathan G Richards; Patricia K Sauter; Eugene P Kennedy; Agnes Witkiewicz; Jonathan R Brody; Charles J Yeo
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

4.  Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Authors:  Maria C Villarroel; N V Rajeshkumar; Ignacio Garrido-Laguna; Ana De Jesus-Acosta; Siân Jones; Anirban Maitra; Ralph H Hruban; James R Eshleman; Alison Klein; Daniel Laheru; Ross Donehower; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-12-06       Impact factor: 6.261

5.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

6.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Authors:  Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo
Journal:  Surgery       Date:  2006-08-28       Impact factor: 3.982

7.  Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.

Authors:  Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

8.  Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.

Authors:  Stefano Crippa; Roberto Salvia; Andrew L Warshaw; Ismael Domínguez; Claudio Bassi; Massimo Falconi; Sarah P Thayer; Giuseppe Zamboni; Gregory Y Lauwers; Mari Mino-Kenudson; Paola Capelli; Paolo Pederzoli; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

9.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

10.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Authors:  Pedro A Pérez-Mancera; Alistair G Rust; Louise van der Weyden; Glen Kristiansen; Allen Li; Aaron L Sarver; Kevin A T Silverstein; Robert Grützmann; Daniela Aust; Petra Rümmele; Thomas Knösel; Colin Herd; Derek L Stemple; Ross Kettleborough; Jacqueline A Brosnan; Ang Li; Richard Morgan; Spencer Knight; Jun Yu; Shane Stegeman; Lara S Collier; Jelle J ten Hoeve; Jeroen de Ridder; Alison P Klein; Michael Goggins; Ralph H Hruban; David K Chang; Andrew V Biankin; Sean M Grimmond; Lodewyk F A Wessels; Stephen A Wood; Christine A Iacobuzio-Donahue; Christian Pilarsky; David A Largaespada; David J Adams; David A Tuveson
Journal:  Nature       Date:  2012-04-29       Impact factor: 49.962

View more
  33 in total

1.  Identification of genes highly downregulated in pancreatic cancer through a meta-analysis of microarray datasets: implications for discovery of novel tumor-suppressor genes and therapeutic targets.

Authors:  Nalin C W Goonesekere; Wyatt Andersen; Alex Smith; Xiaosheng Wang
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-29       Impact factor: 4.553

2.  Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

Authors:  Anne Guyot; Mathilde Duchesne; Sandrine Robert; Anne-Sophie Lia; Paco Derouault; Erwan Scaon; Leslie Lemnos; Henri Salle; Karine Durand; François Labrousse
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

3.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.

Authors:  Erick Riquelme; Yu Zhang; Liangliang Zhang; Maria Montiel; Michelle Zoltan; Wenli Dong; Pompeyo Quesada; Ismet Sahin; Vidhi Chandra; Anthony San Lucas; Paul Scheet; Hanwen Xu; Samir M Hanash; Lei Feng; Jared K Burks; Kim-Anh Do; Christine B Peterson; Deborah Nejman; Ching-Wei D Tzeng; Michael P Kim; Cynthia L Sears; Nadim Ajami; Joseph Petrosino; Laura D Wood; Anirban Maitra; Ravid Straussman; Matthew Katz; James Robert White; Robert Jenq; Jennifer Wargo; Florencia McAllister
Journal:  Cell       Date:  2019-08-08       Impact factor: 41.582

4.  Vascular Resections in Association With Pancreatic Resections for Locally Advanced Pancreatic Cancer.

Authors:  Nicolae Bacalbasa; Irina Balescu; Ion Barbu; Ovidiu Stiru; Cornel Savu; Lucian Pop; Adnan Al Aloul; Bogdan Ursut; Vladislav Brasoveanu; Sorin Petrea
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

5.  ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarcinoma.

Authors:  Hao Hu; Shuo Zhang; Shuming Xiong; Benshun Hu; Youzhao He; Yuanlong Gu
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 6.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

Review 7.  Pancreatic cancer surgery: past, present, and future.

Authors:  James F Griffin; Katherine E Poruk; Christopher L Wolfgang
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

Review 8.  Macrophages and pancreatic ductal adenocarcinoma.

Authors:  Aida Habtezion; Mouad Edderkaoui; Stephen J Pandol
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

9.  Long-term survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Alexander P Stark; Greg D Sacks; Matthew M Rochefort; Timothy R Donahue; Howard A Reber; James S Tomlinson; David W Dawson; Guido Eibl; O Joe Hines
Journal:  Surgery       Date:  2016-02-02       Impact factor: 3.982

Review 10.  From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions.

Authors:  Catherine G Fischer; Laura D Wood
Journal:  J Pathol       Date:  2018-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.